A Glimpse in the Future of Malignant Mesothelioma Treatment

Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2021-12, Vol.12, p.809337-809337
Main Authors: Pezzicoli, Gaetano, Rizzo, Mimma, Perrone, Martina, Minei, Silvia, Mutti, Luciano, Porta, Camillo
Format: Article
Language:English
Subjects:
antiangiogenics
immune checkpoint inhibitors
mesothelin
mesothelioma
microRNA
oncolytic viruses
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.809337